Ani Pharmaceuticals (ANIP) Assets Average (2011 - 2026)

Ani Pharmaceuticals (ANIP) has 16 years of Assets Average data on file, last reported at $1.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 11.08% year-over-year to $1.4 billion; the trailing twelve-month figure through Mar 2026 stood at $1.4 billion (up 11.08% YoY), and the FY2025 full-year result was $1.4 billion, up 24.49% from the prior year.
• Assets Average steadied at $1.4 billion in Q1 2026, from $1.4 billion in the prior quarter.
• In the past five years, Assets Average ranged from a high of $1.4 billion in Q1 2026 to a low of $745.2 million in Q3 2022.
• A 5-year average of $1.0 billion and a median of $909.5 million in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average soared 63.93% in 2022 and climbed 0.58% in 2023, its largest moves.
• Tracing ANIP's Assets Average over 5 years: stood at $749.6 million in 2022, then rose by 19.69% to $897.2 million in 2023, then surged by 43.33% to $1.3 billion in 2024, then climbed by 10.76% to $1.4 billion in 2025, then grew by 0.49% to $1.4 billion in 2026.
• Business Quant data shows ANIP's Assets Average at $1.4 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.4 billion in Q3 2025.